Dapagliflozin Shows Promise in Treating MASH and Liver Fibrosis: BMJ-Published Chinese Trial Offers New Hope
A recent clinical trial in China, published in The BMJ, has revealed that dapagliflozin, a drug commonly used to treat type 2 diabetes, shows significant potential in treating metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis—two progressive liver conditions with limited current treatment options. 🔬 About the Study Participants’ body weight, blood sugar, liver enzymes, blood…
